Author at Microdose

James Hallifax

James Hallifax is a writer and journalist who covers the psychedelic medicines space. After originally founding The Psychedelic Investor, James worked with Psychedelic Spotlight for a year, before going freelance. He now writes weekly for Microdose.buzz, and other publications.

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Industry

25 Jan 2023

Small Pharma DMT Depression Trial: 57% of Patients Enter Remission

Small Pharma Phase 2a trial results....

By James Hallifax

Industry

18 Jan 2023

Microdosing DMT to Treat Strokes: Not as Trippy as it Sounds

On January 17th, the company Algernon Pharmaceuticals announced that they had dosed the first patient in their Phase 1 safety trial of the psychedelic drug DMT to treat stroke patients....

By James Hallifax

Industry

11 Jan 2023

Key Takeaways from MindMed’s 2023 Corporate Update

On January 9th, psychedelic medicine company MindMed (Nasdaq: MNMD, NEO:MMED) released its 2023 corporate update....

By James Hallifax

Law & Politics

5 Jan 2023

Psilocybin Therapy is Now Legal in Oregon — But There’s a Catch

On January 1st, Oregon became the first state in the USA to legalize psilocybin therapy....

By James Hallifax

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

28 Dec 2022

2022 Review: 3 Trials Pushing Boundaries of Psychedelic Medicine

James Hallifax takes a look at 3 psychedelic Clinical Trials Pushing Boundaries of Psychedelic Medicine in 2022...

By James Hallifax

Industry

20 Dec 2022

Top 5 Psychedelic Milestones of 2022

2022 was a big year for psychedelic medicine industry, we take a look at the top 5 psychedelic milestones for 2022...

By James Hallifax

Industry, Law & Politics

8 Dec 2022

Oregon’s Psilocybin Healing Centers: What You Need to Know

Psychedelic medicine advocates are anticipating the opening of Oregon’s legal psilocybin healing centers....

By James Hallifax

Industry, Science

30 Nov 2022

New MindMed Study Shortens Trip with “LSD-Neutralizer”

MindMed collaborators published a paper showing that the administration of ketanserin, effectively ends LSD’s psychedelic experience within 2....

By James Hallifax

Industry

25 Nov 2022

When Will MDMA be Approved by the FDA?

Now that MAPS’ second Phase 3 trial has finished, it is only natural to ask the question: when will MDMA-assisted therapy for PTSD become legal?...

By James Hallifax

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Follow us on social

Latest News

You Might Also Like

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts

10 Oct 2025

After the Billion-Dollar Psychedelic Bet: Who’s Next for Big Pharma?

In the wake of Gilgamesh’s billion-dollar exit, a new wave of companies is emerging, smaller, stealthier, and far more scientifically disciplined than their first-wave predecessors. Their mission: harness the therapeutic...

By Madison Roberts

James Hallifax is a writer and journalist who covers the psychedelic medicines space. After originally founding The Psychedelic Investor, James worked with Psychedelic Spotlight for a year, before going freelance. He now writes weekly for Microdose.buzz, and other publications.

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Follow us on social

WordPress Ads